Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-880 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| VX-880 | EXPERIMENTAL | - |
| VX-017 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VX-880 | BIOLOGICAL | Infused into the hepatic portal vein. |
| VX-017 | BIOLOGICAL | Infused into the hepatic portal vein. |
Key Inclusion Criteria: * Clinical history of T1D with \>=5 years of duration of insulin dependence * At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment * Stable diabetic treatment * Consistent use of continuous glucose monitor (CGM) for at least 3 months b...
VX-880 is an investigational therapy being developed for the treatment of Type 1 Diabetes Mellitus, including cases with impaired hypoglycemic awareness and severe hypoglycemia. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
VX-880 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company is conducting clinical trials to evaluate the safety, tolerability, and efficacy of VX-880 in participants with Type 1 Diabetes.
VX-880 is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and effectiveness for treating Type 1 Diabetes.
VX-880 is being studied in a Phase 3 clinical trial with the identifier NCT04786262. This recruiting study evaluates VX-880 and VX-017 in participants with Type 1 Diabetes, impaired hypoglycemic awareness, and severe hypoglycemia, with an enrollment target of 57 participants across multiple countries.
The specific molecular target of VX-880 has not been disclosed. VX-880 is a monoclonal antibody being investigated for its potential role in treating Type 1 Diabetes, but its mechanism of action has not been publicly detailed in the available clinical trial information.